A comparison of patterns of spontaneous adverse drug reaction reporting with St. John's Wort and fluoxetine during the period 2000-2013

Clinical and Experimental Pharmacology and Physiology

Volumn 42, Issue 7, 2015, Pages 747-751

  Hoban, Claire L ^a   Byard, Roger W ^a   Musgrave, Ian F ^a  

^a UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

Antidepressants; Anxiety; CAMs; Depression; Hypericum perforatum; Pharmacovigilance; Toxicology

Indexed keywords

FLUOXETINE; HYPERICUM PERFORATUM EXTRACT; PLANT MEDICINAL PRODUCT;

ADOLESCENT; ADULT; ARTICLE; CENTRAL NERVOUS SYSTEM; CENTRAL NERVOUS SYSTEM DISEASE; CHILD; CONTROLLED STUDY; DISEASE CLASSIFICATION; DISEASE SEVERITY; DRUG EFFECT; DRUG SURVEILLANCE PROGRAM; FATALITY; FEMALE; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; ORGAN SYSTEMS; SEX DIFFERENCE; TREATMENT OUTCOME; TREATMENT RESPONSE; ADVERSE EFFECTS; AGED; COMPARATIVE STUDY; HYPERICUM; NEWBORN; PRESCHOOL CHILD; STATISTICS AND NUMERICAL DATA; YOUNG ADULT;

ADOLESCENT; ADULT; ADVERSE DRUG REACTION REPORTING SYSTEMS; AGED; CHILD; CHILD, PRESCHOOL; FEMALE; FLUOXETINE; HUMANS; HYPERICUM; INFANT; INFANT, NEWBORN; MALE; MIDDLE AGED; PLANT PREPARATIONS; YOUNG ADULT;

EID: 84933530274     PISSN: 03051870     EISSN: 14401681     Source Type: Journal    
DOI: 10.1111/1440-1681.12424     Document Type: Article

References (26)

1. Byard RW, Musgrave I. Herbal medicines and forensic investigations. Forensic Sci. Med. Pathol. 2010; 6: 81-2.
2. Neergheen-Bhujun VS. Underestimating the toxicological challenges associated with the use of herbal medicinal products in developing countries. BioMed. Res. Int. 2013; 2013: 804086.
3. Butterweck V, Schmidt M. St. John's wort: Role of active compounds for its mechanism of action and efficacy. Wien. Med. Wochenschr. (1946) 2007; 157: 356-61.
4. Hammerness P, Basch E, Ulbricht C et al. St John's wort: A systematic review of adverse effects and drug interactions for the consultation psychiatrist. Psychosomatics 2003; 44: 271-82.
5. Rahimi R, Nikfar S, Abdollahi M. Efficacy and tolerability of Hypericum perforatum in major depressive disorder in comparison with selective serotonin reuptake inhibitors: A meta-analysis. Prog. Neuropsychopharmacol. Biol. Psychiatry 2009; 33: 118-27.
6. Fava M, Alpert J, Nierenberg AA et al. A Double-blind, randomized trial of St John's wort, fluoxetine, and placebo in major depressive disorder. J. Clin. Psychopharmacol. 2005; 25: 441-7.
7. Gastpar M, Singer A, Zeller K. Comparative efficacy and safety of a once-daily dosage of hypericum extract STW3-VI and citalopram in patients with moderate depression: A double-blind, randomised, multicentre, placebo-controlled study. Pharmacopsychiatry 2006; 39: 66-75.
8. Moreno RA, Teng CT, Almeida KM. Tavares Junior H. Hypericum perforatum versus fluoxetine in the treatment of mild to moderate depression: A randomized double-blind trial in a Brazilian sample. Rev. Bras. Psiquiatr. (Sao Paulo, Brazil: 1999) 2006; 28: 29-32.
9. Rapaport MH, Nierenberg AA, Howland R, Dording C, Schettler PJ, Mischoulon D. The treatment of minor depression with St. John's Wort or citalopram: Failure to show benefit over placebo. Psychiatry Res. 2011; 45: 931-41.
10. Byard RW. A review of the potential forensic significance of traditional herbal medicines. J. Forensic Sci. 2010; 55: 89-92.
11. Lau AJ, Holmes MJ, Woo SO, Koh HL. Analysis of adulterants in a traditional herbal medicinal product using liquid chromatography-mass spectrometry-mass spectrometry. J. Pharm. Biomed. Anal. 2003; 31: 401-6.
12. Ernst E. Adulteration of Chinese herbal medicines with synthetic drugs: A systematic review. J. Inern. Med. 2002; 252: 107-13.
13. Kostakis C, Byard RW. Sudden death associated with intravenous injection of toad extract. Forensic Sci. Int. 2009; 188: e1-5.
14. Schellander R, Donnerer J. Antidepressants: Clinically relevant drug interactions to be considered. Pharmacology 2010; 86: 203-15.
15. Inch J, Watson MC, Anakwe-Umeh S. Patient versus healthcare professional spontaneous adverse drug reaction reporting: A systematic review. Drug Saf. 2012; 35: 807-18.
16. Ribeiro-Vaz I, Santos C, da Costa-Pereira A, Cruz-Correia R. Promoting spontaneous adverse drug reaction reporting in hospitals using a hyperlink to the online reporting form: An ecological study in Portugal. Drug Saf. 2012; 35: 387-94.
17. MacLennan AH, Wilson DH, Taylor AW. Prevalence and cost of alternative medicine in Australia. Lancet 1996; 347: 569-73.
18. MacLennan AH, Wilson DH, Taylor AW. The escalating cost and prevalence of alternative medicine. Prev. Med. 2002; 35: 166-73.
19. MacLennan AH, Myers SP, Taylor AW. The continuing use of complementary and alternative medicine in South Australia: Costs and beliefs in 2004. Med. J. Aust. 2006; 184: 27-31.
20. Byard RW, James RA, Felgate P. Detecting organic toxins in possible fatal poisonings-a diagnostic problem. J. Clin. Forensic Med. 2002; 9: 85-8.
21. Rahman SZ, Basilakis J, Rahmadi A et al. Use of serotonergic antidepressants and St John's wort in older Australians: A population-based cohort study. Australas. Psychiatry 2013; 21: 262-6.
22. Borrelli F, Izzo AA. Herb-drug interactions with St John's wort (Hypericum perforatum): An update on clinical observations. AAPS J. 2009; 11: 710-27.
23. Licata A, Macaluso FS, Craxi A. Herbal hepatotoxicity: A hidden epidemic. Intern. Emerg. Med. 2013; 8: 13-22.
24. World Health Organization, Introduction to the WHO Programme for International Drug Monitoring, c2014. Available from: http://who-umc2010.phosdev.se/DynPage.aspx?id&=&98080&mn1&=&7347&mn2&=&7252&mn3&=&7322&mn4&=&7324 (accessed 23 March 2015).
25. Hartwig SC, Siegel J, Schneider PJ. Preventability and severity assessment in reporting adverse drug reactions. Am. J. Hosp. Pharm. 1992; 49: 2229-32.
26. Privacy Act of 1988, Australia, c2014. Available from: http://www.comlaw.gov.au/Details/C2014C00757 (accessed 23 March 2015).